Follow up of Ticagrelor Treatment Patterns in Chinese Acute Coronary Syndromes Patients- A Database Retrospective Study
试验速览
- 阶段
- 不适用
- 入组人数
- 20,000
- 试验地点
- 1
- 主要终点
- Ticagrelor persistence
研究概览
简要总结
This is a retrospective, observational, descriptive study which will include patients hospitalized for acute coronary syndrome (ACS) and treated with ticagrelor at discharge. Participants will come from the follow-up program of ACS patients taking ticagrelor 90 mg twice a day as part of the dual antiplatelet therapy at discharge. The primary objectives were to describe the ticagrelor treatment patterns-Ticagrelor persistence, discontinuation, switching, interruption and reasons in Chinese ACS patients; and also to describe 1-year clinical outcomes (Composite of any cause death, myocardial infarction, and stroke) of Chinese ACS patients in real-life practice based on ACS patient follow-up program database.
详细描述
Background： There are at least 2.5 million acute coronary syndromes (ACS) patients in China per year. Limited data about long term ticagrelor treatment patterns and clinical outcomes in Chinese ACS patients due to the lack of large high quality follow up database. This study is based on real-life practice and ticagrelor is prescribed according to the Chinese guideline and it takes place in real life.
Objective of this study:
Primary Objectives:
- To describe the ticagrelor treatment patterns-Ticagrelor persistence, discontinuation, switching, interruption and reasons for discontinuation/switching/interruption in Chinese ACS patients.
- To describe 1-year clinical outcomes (Composite of any cause death, myocardial infarction, and stroke) of Chinese ACS patients in real-life practice based on ACS patient follow-up program database.
Secondary Objectives:
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •ACS patients hospitalized during the following period: from January 2019 to September 2019
- •Patients receiving ticagrelor as part of DAPT at hospital discharge.
- •Patient enrolled into the follow-up program of ACS patients
排除标准
- •Patients participated in other interventional clinical trials
结局指标
主要结局
Ticagrelor persistence
时间窗: 12 months
Duration of ticagrelor treatment: Proportion of patients receiving ticagrelor each month after discharge; Duration from the start of treatment to the end of treatment.
Ticagrelor switch and reasons for switching
时间窗: 12 months
Percentage of patients with ticagrelor change and related causes: Switching refers to switching from ticagrelor/clopidogrel to another P2Y12 inhibitor (switching from clopidogrel to ticagrelor is a redressing, if documented)
Ticagrelor discontinuation and reasons for discontinuation
时间窗: 12 months
Percentage of patients with ticagrelor discontinuation and related causes: Discontinuation was defined as stopping P2Y12 for at least 3 months.
Ticagrelor interruption and reasons for interruption
时间窗: 12 months
Percentage of patients with ticagrelor interruption and related causes: Interruptionn was defined as drug withdrawal for more than 1 day and less than 3 months.
Major Adverse Cardiovascular Events
时间窗: 12 months
Time to the first occurence of Any cause death, myocardial infarction, or Stroke
次要结局
- Any cause death(12 months)
- Stroke(12 months)
- Myocardial infarction(12 months)
研究者
Yong Huo
Former director of the Department of cardiology, Principal Investigator, Clinical professor
Peking University First Hospital